Granisetron News and Research

RSS
Granisetron is the active ingredient in a drug used to treat nausea and vomiting caused by cancer treatment. Granisetron is a type of serotonin receptor antagonist and a type of antiemetic.
Researchers identify neural circuit involved in reciprocally regulating weight gain and depression

Researchers identify neural circuit involved in reciprocally regulating weight gain and depression

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Certain anti-nausea medications used after operation could increase risk for irregular heartbeat

Certain anti-nausea medications used after operation could increase risk for irregular heartbeat

Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

FDA accepts A.P. Pharma’s resubmission of NDA for APF530

FDA accepts A.P. Pharma’s resubmission of NDA for APF530

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

A.P. Pharma resubmits APF530 NDA with FDA for prevention of CINV

A.P. Pharma resubmits APF530 NDA with FDA for prevention of CINV

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

Positive results from Acacia Phase II APD421 study in prevention of post-operative nausea & vomiting

Positive results from Acacia Phase II APD421 study in prevention of post-operative nausea & vomiting

BDSI announces postponement of ONSOLIS U.S. relaunch

BDSI announces postponement of ONSOLIS U.S. relaunch

USPTO rejects MonoSol's patent infringement claims against BDSI

USPTO rejects MonoSol's patent infringement claims against BDSI

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

A.P. Pharma's third quarter net loss increases to $4.2 million

A.P. Pharma's third quarter net loss increases to $4.2 million

Positive results from BDSI's BEMA Buprenorphine/Naloxone formulation Phase 1 study on opioid dependence

Positive results from BDSI's BEMA Buprenorphine/Naloxone formulation Phase 1 study on opioid dependence

A.P. Pharma second quarter net loss decreases to $1.9 million

A.P. Pharma second quarter net loss decreases to $1.9 million

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA